Company Overview

cbdMD, Inc. (NYSE American: YCBD) is a U.S.-based consumer wellness company focused on hemp-derived cannabidiol (CBD) products and related cannabinoid formulations. The company operates within the broader health, wellness, nutraceutical, and personal care industries, with product offerings spanning tinctures, gummies, capsules, topical products, sleep aids, pet wellness products, and functional mushroom formulations. cbdMD primarily generates revenue through direct-to-consumer e-commerce sales, retail distribution partnerships, and specialty health and wellness channels.

The company’s core brands include cbdMD, Paw CBD, and selected wellness-focused product extensions tied to cannabinoids and plant-based ingredients. cbdMD positions itself around broad-spectrum and THC-free hemp products, emphasizing third-party testing, consumer transparency, and premium branding within a highly fragmented CBD market. The business originated through a series of corporate restructurings and acquisitions involving Cure Based Development, Level Brands, and related entities before adopting the cbdMD corporate identity and expanding nationally following the passage of the 2018 U.S. Farm Bill, which legalized hemp cultivation under federal law.

Business Operations

cbdMD operates primarily through branded consumer wellness segments centered on hemp-derived products. The company’s principal operating platforms include cbdMD for human wellness products and Paw CBD for pet-focused cannabinoid offerings. Revenue is generated through online sales, subscription programs, retail partnerships, distributors, and selected wholesale relationships. The company has historically emphasized digital marketing, athlete and influencer partnerships, and brand-driven customer acquisition strategies to support sales growth.

Operations are concentrated in the United States, although the company has pursued selective international distribution opportunities where regulations permit hemp-derived wellness products. cbdMD relies on third-party manufacturing and supply-chain partners while maintaining control over product formulation standards, branding, testing protocols, and marketing operations. The company has also maintained relationships with sports organizations, athletes, and wellness ambassadors to strengthen consumer visibility and brand recognition in competitive CBD categories.

Strategic Position & Investments

cbdMD’s strategic direction has focused on expanding branded wellness offerings, improving operating efficiency, and strengthening customer retention in a market characterized by pricing pressure and evolving regulation. The company has invested in product diversification beyond traditional CBD categories, including sleep support products, botanicals, adaptogens, and functional wellness formulations designed to broaden its consumer base. Management has also emphasized disciplined cost controls and inventory management following broader industry slowdowns in the U.S. CBD market.

The company has pursued acquisitions and brand portfolio expansion as part of its growth strategy. Historical transactions involving Paw CBD and related wellness assets contributed to cbdMD’s multi-brand structure. cbdMD has also explored opportunities tied to emerging cannabinoid categories, including formulations incorporating minor cannabinoids where legally permissible. Public filings indicate continued focus on brand positioning, retail expansion, and strategic marketing partnerships rather than large-scale manufacturing ownership or international infrastructure buildouts.

Geographic Footprint

cbdMD is headquartered in Charlotte, North Carolina, and its primary operational focus remains the United States market. The company distributes products nationally through e-commerce channels and retail networks that include health retailers, wellness stores, and selected mass-market distribution relationships. Its customer base is concentrated in North America, where hemp-derived wellness products have greater regulatory clarity and consumer adoption.

The company has pursued limited international distribution opportunities in regions where hemp-derived CBD products are legally permitted, including select markets in Europe and other international jurisdictions through distributors or online fulfillment arrangements. However, cbdMD’s operational scale and commercial concentration remain predominantly U.S.-centric relative to larger multinational wellness and consumer packaged goods companies.

Leadership & Governance

cbdMD’s leadership team has focused on brand development, operational restructuring, and navigating the evolving regulatory environment surrounding cannabinoid-based consumer products. The company’s governance structure reflects its status as a publicly traded wellness company subject to U.S. securities reporting requirements and exchange governance standards. Strategic priorities communicated by leadership have included profitability improvement, customer acquisition efficiency, brand differentiation, and expansion into adjacent wellness categories.

Key executives and leadership figures include:

• Ronald L. Marshall – Chairman and Chief Executive Officer
• Mark H. Gwazdauskas – Chief Financial Officer
• Caryn Dunayer – Executive Vice President and Chief Marketing Officer

Public disclosures and corporate filings indicate that management continues to prioritize operational discipline, brand positioning, and long-term participation in the regulated cannabinoid wellness market. Certain leadership roles and organizational structures have changed periodically in response to restructuring initiatives and broader market conditions.